|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
We conducted a case-control study (4,059 cases and 4,059 matched controls) nested within the E3N French cohort study to estimate the risk of breast cancer associated with long-term exposure to airborne cadmium pollution, and its effect according to molecular subtype of breast cancer (estrogen receptor negative/positive [ER-/ER+] and progesterone receptor negative/positive [PR-/PR+]).
|
30851122 |
2020 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
In general, associations of risk factors for ER+ DCIS were similar in magnitude and direction to those for invasive ER+ breast cancer.
|
31786415 |
2020 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Most importantly, high HMGA1 predicted decreased overall survival (P < 0.0001) for all women with breast cancer and further stratified ER-positive tumors into those with inferior outcomes.
|
31531802 |
2020 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Endocrine therapy resistance in breast cancer is a major obstacle in the treatment of patients with estrogen receptor-positive (ER+) tumors.
|
31595691 |
2020 |
|
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Correction to: Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy.
|
31734822 |
2020 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The aim of the present study was to investigate the anti-proliferative and cytotoxic effects of CCT137690 on estrogen receptor (ER)-positive human breast cancer cell line (MCF-7) and ER-negative human breast cancer cell line (MDA-MB-231).
|
31319040 |
2020 |
|
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The AP-2γ transcription factor, encoded by the <i>TFAP2C</i> gene, regulates the expression of estrogen receptor-alpha (ERα) and other genes associated with hormone response in luminal breast cancer.
|
31619506 |
2020 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
We aimed to compare stemness profile of two major subtypes [Estrogen receptor positive (ER<sup>+</sup>) and negative (ER<sup>-</sup>)] breast cancer using different sets of markers.
|
30361903 |
2020 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
In the present study, we investigated the effects of lupiwighteone on the proliferation and apoptosis of two different human cancer cells; MCF-7, an estrogen receptor (ER)-positive human breast cancer cell, and MDA-MB-231, a triple negative human breast cancer cell.
|
31604113 |
2020 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Breast cancer (BC) is the most common cancer in women, where hormone receptor-positive (HR+; estrogen receptor and/or progesterone receptor) BC comprises the majority (>50%) and has better prognosis, while a minority (<20%) are triple negative BC (TNBC), which has an aggressive phenotype.
|
31502168 |
2020 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
A great hallmark of breast cancer is the absence or presence of estrogen receptors ERα and ERβ, with a dominant role in cell proliferation, differentiation and cancer progression.
|
31401293 |
2020 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b><i>CYP2D6*10</i> pharmacogenetic-guided selective estrogen receptor modulator can be a cost-effective strategy in the Chinese patients with hormone receptor-positive breast cancer.
|
31769341 |
2020 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Women with ER-negative disease or breast cancer diagnosis within the first follow-up year were excluded.
|
31187481 |
2020 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Ax-pCR was more likely to be achieved in patients who were diagnosed with ER-negative and high-grade breast cancer and those with ycN0 and clinical CR at the primary site after NAC than among others.
|
31367884 |
2020 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
This focused review highlights recent achievements in pre-clinical and clinical imaging of ER and PR in breast cancer.
|
31732674 |
2020 |
|
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy.
|
31562570 |
2020 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
rs2234693 and rs9340799 polymorphisms in the ESR1 gene were not associated with susceptibility for BC.
|
31786857 |
2020 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China.
|
31559573 |
2020 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
In this paper, we present a prospective observational study, which determines the incidence of bone metastases and its correlation with hormonal receptors (estrogen receptor [ER]/progesterone receptor [PR]) and human epidermal growth factor receptor 2 (HER2) in breast cancer.
|
31603096 |
2020 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Combination with BRAF/MEK pathway activities could improve ER status-based recurrence prediction for breast cancer.
|
31547956 |
2020 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Alcohol intake was positively associated with overall BC risk and specifically with estrogen receptor-positive tumors with respectively TE = 1.17(95%CI: 1.01,1.35) and 1.36(1.08,1.70) for a 1-standard deviation (1-SD) increase of intake.
|
30968961 |
2020 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Patients with estrogen receptor-expressing early-stage operable breast cancer who received depomedroxyprogesterone acetate for hot flashes between January 2005 and December 2012 were identified.
|
31402403 |
2020 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the ligand-binding domain (LBD) of the ESR1 gene result in resistance to estrogen deprivation therapy (EDT) in breast cancer.
|
31669227 |
2020 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) are the three crucial biomarkers for the clinical diagnosis of breast cancer.
|
31665670 |
2020 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Using an unbiased cell line screening approach, we tested the sensitivity of breast cancer cell lines to taselisib, a potent PI3K inhibitor, and correlated sensitivity with key biomarkers (PIK3CA, HER2, PTEN, ESR1).
|
31534012 |
2020 |